Furthermore, elevated AnxA6 scaffold levels contributed to improving the efficacy of tyrosine kinase inhibitors (TKIs) targeting EGFR to reduce growth, migration, and invasive properties of EGFR overexpressing A431 carcinoma cells [240,241,242,245]. Here, ANXA6 is linked to carcinoma.